Panel A summarizes the conventional model of how oncogenic RAS guanosine triphosphatases (i.e., Kirsten rat sarcoma viral oncogene homologue [KRAS], neuroblastoma RAS viral oncogene homologue ...
Lumakras and Vectibix combination approved for KRAS G12C-mutated mCRC after specific chemotherapy regimens. CodeBreaK 300 trial showed improved progression-free survival with Lumakras/Vectibix ...
The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free survival. The approval was based on results from CodeBreaK 300 ...
This new option validates our combination approach to improve outcomes for patients living with advanced KRAS G12C-mutated metastatic colorectal cancer." The CodeBreaK 300 clinical trial compared ...
Amgen's first-to-market KRAS inhibitor Lumakras has so far failed to live up to once-lofty sales expectations, but a new FDA approval could lend momentum to its growth. The US regulator has ...
GuruFocus has detected 6 Warning Signs with AMGN. The decision, announced Thursday, applies to adults whose tumors carry the KRAS G12C mutation. Amgen's treatment pairs Lumakras (sotorasib ...
AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...
Brno - Moravský kras je po dnešku ještě lákavějším místem k jarnímu výletu. Stovky dětí v chráněné oblasti vysbíraly odpadky po turistech a zaplnily jimi hned několik kontejnerů. Odpoledne je za ...
Amgen’s Lumakras has secured an FDA approval in combination with the drugmaker’s Vectibix for a subset of patients with metastatic colorectal cancer, marking a ...
NEW YORK – The US Food and Drug Administration on Thursday approved Amgen's KRAS inhibitor Lumakras (sotorasib) with its EGFR monoclonal antibody Vectibix (panitumumab) for previously treated patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback